Buprenorphine for acute heroin detoxification: Diffusion of research into practice

Journal of Substance Abuse Treatment

Volumn 32, Issue 2, 2007, Pages 199-206

  Kovas, Anne E ^a   McFarland, Bentson H ^a,b   McCarty, Dennis J ^b   Boverman, Joshua F ^a   Thayer, James A ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Hooper Detoxification Center   (United States)

Author keywords

Community based treatment; Heroin detoxification; Length of stay; Treatment completion; Treatment diffusion; Treatment engagement

Indexed keywords

BUPRENORPHINE; CLONIDINE;

ADULT; ARTICLE; BIVARIATE ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; DRUG DOSE REDUCTION; FEMALE; HEROIN DEPENDENCE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL RECORD REVIEW; MEDICAL RESEARCH; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; BUPRENORPHINE; CLONIDINE; DIFFUSION OF INNOVATION; FEMALE; HEROIN; HEROIN DEPENDENCE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NARCOTICS; OREGON; PATIENT ACCEPTANCE OF HEALTH CARE; RETROSPECTIVE STUDIES; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 33846910526     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2006.08.003     Document Type: Article

References (49)

1. Amass L., Bickel W.K., Higgins S.T., and Hughes J.R. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. Journal of Addictive Diseases 13 (1994) 33-45
2. Amass L., Ling W., Freese T.E., Reiber C., Annon J.J., Cohen A.J., et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience. American Journal on Addictions 13 (2004) S42-S66
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Psychiatric Association, Washington, DC
4. Bickel W.K., Stitzer M.L., Bigelow G.E., Liebson I.A., Jasinski D.R., and Johnson R.E. Buprenorphine: Dose-related blockade of opioid challenge effects in opioid dependent humans. Journal of Pharmacology and Experimental Therapeutics 247 (1988) 47-53
5. Bodenheimer T., Wagner E.H., and Grumbach K. Improving primary care for patients with chronic illness. Journal of the American Medical Association 288 (2002) 1775-1779
6. Brown B.S., O'Grady K.E., Battjes R.J., and Katz E.C. The Community Assessment Inventory-Client views of supports to drug abuse treatment. Journal of Substance Abuse Treatment 27 (2004) 241-251
7. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction (TIP 40) (2004), U.S. Department of Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, Rockville, MD
8. Charney D.S., Stenberg D.E., Kleber H.D., Hensinger G.R., and Redmond D.E. The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms. Archives of General Psychiatry 42 (1981) 1273-1277
9. Cheskin L.J., Fudala P.J., and Johnson R.E. A controlled comparison of buprenorphine and clonidine for acute detoxification from opiates. Drug and Alcohol Dependence 36 (1994) 115-121
10. Diamant K., Fischer G., Schneider C., Lenzinger E., Pezawas L., Schindler S., et al. Outpatient opiate detoxification treatment with buprenorphine: Preliminary investigation. European Addiction Research 4 (1998) 198-202
11. Fudala P.J., Bridge T.P., Herbert S., Williford W.O., Chiang C.N., Jones K., et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine 349 (2003) 949-958
12. Gold M.S., Redmond D.E., and Kleber H.D. Clonidine blocks acute opiate-withdrawal symptoms. Lancet 2 (1978) 599-602
13. Gossop M. Clonidine and the treatment of opiate withdrawal syndrome. Drug and Alcohol Dependence 21 (1988) 253-259
14. Gossop M., Green L., Phillips G., and Bradley B. Lapse, relapse, and survival among opiate addicts after treatment: A prospective follow-up study. British Journal of Psychiatry 154 (1989) 348-353
15. Hser Y.I., Hoffman V., Grella C.E., and Anglin D. A 33-year follow-up of narcotics addicts. Archives of General Psychiatry 58 (2001) 503-508
16. Jasinski D.R., Pevnick J.S., and Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine. Archives of General Psychiatry 35 (1978) 501-516
17. Johnson R.E., Strain E.C., and Amass L. Buprenorphine: How to use it right. Drug and Alcohol Dependence 70 (2003) S59-S77
18. Join Together. National poll of physicians finds barriers to widespread buprenorphine use (2003), Boston University School of Public Health, Boston, MA
19. Kakko J., Svanborg K.D., Kreek M.J., and Heilig M. 1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised placebo-controlled trial. Lancet 361 (2003) 662-668
20. Kintz P. Buprenorphine-related deaths. In: Kintz P., and Marquet P. (Eds). Buprenorphine therapy of opiate addiction (2002), Humana Press, Totowa, NJ 109-118
21. Lewis J.W. Buprenorphine. Drug and Alcohol Dependence 14 (1985) 363-372
22. Ling W., Amass L., Shoptaw S., Annon J.J., Hillhouse M., Babcock D., et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 100 (2005) 1090-1100
23. Ling W., Cunningham-Rathner J., and Rawson R. Diffusion of substance abuse treatment: Will buprenorphine be a success?. Journal of Psychoactive Drugs SARC Supplement 2 (2004) 115-117
24. Lintzeris N. Buprenorphine dosing regime in the management of out-patient heroin withdrawal. Drug and Alcohol Reviews 21 (2002) 39-45
25. Lintzeris N., Bell J., Bammer G., Jolley D.J., and Rushworth L. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction 97 (2002) 1395-1404
26. Mattick R., and Hall W. Are detoxification programmes effective?. Lancet 347 (1996) 97-100
27. McCarty D., Rieckmann T., Green C., Gallon S., and Knudsen J. Training rural practitioners to use buprenorphine: Using The Change Book to facilitate technology transfer. Journal of Substance Abuse Treatment 26 (2004) 203-208
28. McLellan A.T., Lewis D.C., O'Brien C.P., and Kleber H.D. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. Journal of the American Medical Association 284 (2000) 1689-1695
29. Mello N.K., and Mendelson J.H. Buprenorphine suppresses heroin use by heroin addicts. Science 207 (1980) 657-659
30. Nigam A.K., Ray R., and Tripathi B.M. Buprenorphine in opiate withdrawal: A comparison with clonidine. Journal of Substance Abuse Treatment 10 (1993) 391-394
31. NIH Consensus Panel. National consensus development panel on effective medical treatment of opiate addiction. Journal of the American Medical Association 280 (1998) 1936-1943
32. O'Connor P.G., Carroll K.M., Shi J.M., Schottenfeld R.S., Kosten T.R., and Rounsaville B.J. Three methods of opioid detoxification in a primary care setting. A randomized trial. Annals of Internal Medicine 127 (1997) 526-530
33. O'Connor P.G., and Fiellin D.A. Pharmacologic treatment of heroin-dependent patients. Annals of Internal Medicine 133 (2000) 40-54
34. O'Connor P.G., Waugh M.E., Carroll K.M., Rounsaville B.J., Diagkogiannis I.A., and Schottenfeld R.S. Primary care-based ambulatory opioid detoxification: The results of a clinical trial. Journal of General Internal Medicine 10 (1995) 255-260
35. Oreskovich M.R., Saxton A.J., Ellis M.L.K., Malte C.A., Reoux J.P., and Knox P.C. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin. Drug and Alcohol Dependence 77 (2005) 71-79
36. Palmstierna T. Effects of a high-dose fast tapering buprenorphine detoxification program on symptom relief and treatment retention. Journal of Psychoactive Drugs 36 (2004) 273-277
37. Rance M.J., and Dickens J.N. The influence of drug receptor kinetics on the pharmacological and pharmaco-kinetic profiles of buprenorphine. In: Van Ree J.M., and Preniums L. (Eds). Characteristics and function of opioids (1978), Elsevier North-Holland Biomedical Press, Amsterdam 65-66
38. Rounsaville B.J., and Kosten T.R. Treatment for opioid dependence: Quality and access. Journal of the American Medical Association 284 (2000) 1337-1339
39. Schnoll S.H. Treatment of opioid addiction in physicians' offices: It is about time. Journal of Addictive Disease 20 (2001) 1-3
40. Schottenfeld R.S., Pantalon M.V., Chawarski M.C., and Pakes J. Community reinforcement approach for combined opioid and cocaine dependence. Patterns of engagement in alternate activities. Journal of Substance Abuse Treatment 18 (2000) 255-261
41. Sees K.L., Delucchi K.L., Masson C., Rosen A., Clark H.W., Robillard H., et al. Methadone maintenance vs. 180-day psychosocially enriched detoxification of treatment of opioid dependence: A randomized clinical trial. Journal of the American Medical Association 283 (2000) 1303-1310
42. Sigmon S.C., Wong C.J., Chausmer A.L., Liebson I.A., and Bigelow G.E. Evaluation of an injection depot formulation of buprenorphine: Placebo comparison. Addiction 99 (2004) 1439-1449
43. Sobel B.F., Sigmon S.C., Walsh S.L., Johnson R.E., Liebson I.A., Nuwayser E.S., et al. Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug and Alcohol Dependence 73 (2004) 11-22
44. Substance Abuse and Mental Health Services Administration. Discharges from detoxification: 2000. DASIS report (2004), U.S. Department of Health and Human Services, Rockville, MD
45. Substance Abuse and Mental Health Services Administration. Will Medicare and Medicaid cover substance abuse treatment and buprenorphine?. Retrieved on November 8, 2004, from (2004). http://buprenorphine.samhsa.gov/faq.html
46. Thomas C.P., and McCarty D. Adoption of drug abuse treatment technology in specialty and primary care settings. In: Harwood H.J., and Myers T.G. (Eds). New treatments for addiction: Behavioral, ethical, legal, and social questions (2004), National Academies Press, Washington, DC 140-172
47. Thomas C.P., Wallack S.S., Lee S., McCarty D., and Swift R. Research to practice: Adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment 24 (2003) 1-11
48. Washton A.M., and Resnick R.B. Clonidine for opiate detoxification: Outpatient clinical study. American Journal of Psychiatry 137 (1980) 1121-1122
49. Wesson D.R., and Ling W. The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs 35 (2003) 253-259